medigraphic.com
ISSN 2007-6800 (Print)

2024, Number 2

Next >>

Rev Mex Traspl 2024; 13 (2)

Active antibody-mediated rejection in renal transplantation: early detection, current treatment perspectives and future therapeutic options

Gaytán-Arocha JE, Berman-Parks N

Language: Spanish
References: 11
Page: 53-55
PDF size: 121.86 Kb.





REFERENCES

  1. Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018; 379 (12): 1150-1160. Available in: https://doi.org/10.1056/nejmra1802677

  2. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009; 9 (11): 2520-2531. Available in: https://doi.org/10.1111/j.1600-6143.2009.02799.x

  3. Loupy A, Vernerey D, Tinel C, Aubert O, Duong van Huyen JP et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. Journal of the American Society of Nephrology. 2015; 26 (7): 1721-1731. Available in: https://doi.org/10.1681/ASN.2014040399

  4. Okada M, Tomosugi T, Futamura K, Hiramitsu T, Goto N, Narumi S et al. Mid-term outcomes after treatment for antibody-mediated rejection by de novo donor-specific HLA antibody in renal transplant recipients: does early treatment lead to better outcomes? Transplant Proc. 2020; 52 (10): 3051-3057. Available in: https://doi.org/10.1016/j.transproceed.2020.06.022

  5. Naesens M, Roufosse C, Haas M, Lefaucheur C, Mannon RB, Adam BA et al. The banff 2022 kidney meeting report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant. 2024; 24 (3): 338-349. Available in: https://doi.org/10.1016/j.ajt.2023.10.016

  6. Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the transplantion Society Working Group. Transplantation. 2020; 104 (5): 911-922. Available in: https://doi.org/10.1097/TP.0000000000003095

  7. Mayer KA, Budde K, Jilma B, Doberer K, Bohmig GA. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. Expert Opin Emerg Drugs. 2022; 27 (2): 151-167. Available in: https://doi.org/10.1080/14728214.2022.2091131

  8. Moreso F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant. 2018; 18 (4): 927-935. Available in: https://doi.org/10.1111/ajt.14520

  9. Doberer K, Klager J, Gualdoni GA, Mayer KA, Eskandary F, Farkash EA et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation. 2021; 105 (2): 451-457. Available in: https://doi.org/10.1097/TP.0000000000003247

  10. Zhu L, Guo Z, Zhao D, Sa R, Zhao G, Guo H et al. Case report: daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies. Front Immunol. 2023; 13: 1087597. Available in: https://doi.org/10.3389/fimmu.2022.1087597

  11. Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S et al. A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N Engl J Med. 2024. Available in: https://doi.org/10.1056/NEJMoa2400763




2020     |     www.medigraphic.com